In order to solve these problems, different authors have proposed methods to assess insulin sensitivity such as eGDR (estimated glucose disposal rate), but its utility in patients with T1D and MS has not been determined and since it is based on the measurements of waist-to-hip ratio, it has been suggested that cut-off points for each population need to be validated. This evidence concerns the gene INS and myeloid sarcoma.